SAR 438335
Alternative Names: SAR438335Latest Information Update: 13 Feb 2019
At a glance
- Originator Sanofi
- Class Antihyperglycaemics
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2018 Discontinued - Phase-I for Type-2 diabetes mellitus in France (Sanofi pipeline, February 2019)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Type-2 diabetes-mellitus in France
- 31 Oct 2015 Phase-I clinical trials in Type-2 diabetes mellitus in France before October 2015